This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
France's Ipsen Finalizes Purchase of US Biopharmaceutical Group Epizyme MT
Epizyme Announces Management Changes CI
Epizyme, Inc. Appoints Grant Bogle as Chief Executive Officer CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Composite Index CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P TMI Index CI
Epizyme, Inc.(NasdaqGS:EPZM) dropped from NASDAQ Biotechnology Index CI
Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. from RP Management LLC and others. CI
Earnings Flash (EPZM) EPIZYME Reports Q2 Revenue $27.5M MT
Epizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
France's Ipsen Extends Tender Offer To Purchase US Biopharmaceutical Epizyme MT
Hutchmed Starts Bridging Study Follicular Lymphoma Treatment in China MT
North American Morning Briefing : Futures Waver -2- DJ
Cowen Downgrades Epizyme to Market Perform From Outperform; Price Target is $1.50 MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday MT
Wall Street Set for Positive Open, Extending Gains on Easing Inflation Expectations MT
Wedbush Cuts Epizyme to Neutral From Outperform, Price Target to $1.45 From $7, Citing Ipsen Offer MT
Top Premarket Gainers MT
Transcript : Epizyme, Inc., Ipsen S.A. - M&A Call
European shares hit two-week high as China eases COVID-19 curbs RE
Epizyme Agrees to be Acquired by Ipsen for $247 Million MT
France's Ipsen Launches Tender Offer to Purchase US Biopharmaceutical Epizyme MT
Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. from RP Management LLC and others for approximately $250 million. CI
HC Wainwright Adjusts Epizyme's Price Target to $6 From $8, Reiterates Buy Rating MT
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting CI
Chart Epizyme, Inc.
More charts
Logo Epizyme, Inc.
Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The Company's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. It is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The Company is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.
Employees
250
More about the company
  1. Stock Market
  2. Equities
  3. EPZM Stock
  4. News Epizyme, Inc.
  5. Epizyme : Jefferies Downgrades Epizyme to Hold From Buy, Adjusts Price Target to $14 From $18